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Although there is still some resistance to the evidence-based
medicine movement, evidence-based health care has now
become widely accepted and adopted. Systematic reviews of
the effectiveness of health care interventions are the engine
room of evidence-based health care; much has been written
about how these reviews should be conducted and what they
can achieve [1,2]. If the case for the use of systematic reviews
is good in developed countries—and we think it is—then the
case is even stronger in the developing world. Wherever health
care is provided and used, it is essential to know which inter-
ventions work, which do not work, and which are likely to be
harmful. This is especially important in situations where health
problems are severe and the scarcity of resources makes it vital
that they are not wasted [3].
But are the systematic reviews that have so far been pub-
lished relevant and of practical use to those who provide health
care in ‘‘the majority world’’ (i.e., in developing countries? In
our view, the relevance of systematic reviews to frontline
health care workers in developing countries has so far been
limited, for a number of reasons.
Reasons Why the Relevance Is Limited
Conditions
Most of the reviews produced to date address health conditions
that are priorities in the developed world [4]. Many major
health concerns in developing nations have yet to be made
the subject of a review, although there are signs that this may
be changing [5]. The introductory discussions of most reviews
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Western Europe. This may be an indication of the authors’
own priorities and experience, or it may be because they
have made assumptions about the priorities of journal editors
and readers.
Interventions
Health care professionals in developing countries sometimes
wonder whether their reliance on older, cheaper, ‘‘lower-
tech’’ approaches has made their practice quite distinct from
that of their colleagues in richer regions [6]. Yet the authors
of systematic reviews seem, by and large, to prefer to take on
the task of assessing the evidence for more recent (and gener-
ally more expensive) technologies. This is not to say that
reviewers should avoid high-tech interventions. Again, it is a
question of setting priorities, and of recognising the urgent
need for more reviews on interventions that are feasible in
the majority world.
Exclusion of Studies from the Developing World
Systematic reviews are based largely on research that has been
done in rich countries. One of the reasons for this is the relative
lack of research in developing countries. However, even when
research has been conducted in these countries, it might not be
published [7]—or if it is published, it might not be in a journal
that is indexed in the widely used bibliographic databases such
as MEDLINE and EMBASE. Thus, despite the best efforts of
many reviewers, relevant studies may easily be missed.
Excluding studies on the basis of language or region is gener-
ally not considered good practice in systematic reviewing [8],
but the difficulties of identifying and assessing such studies
can make finding them and including them in a review an
unrealistic expectation.
Quality of Studies from the Developing World
Once studies have been found, they are assessed for quality by
the reviewers. Only when the quality meets the criteria speci-
fied in the review protocol (in most cases, this specifies
randomised controlled trials only) are they included in the ana-
lysis. The difficulties of conducting randomized controlled
trials in resource-poor situations result in the exclusion of
many developing country studies. Some have suggested that
the ‘‘quality threshold’’ shouldbe lowered, so that more studies
from developing countries can be included in systematic
reviews. This question is contentious, and indeed divides the
authors of this essay, but it needs to be recognised and debated
openly.
Transferability
Practitioners in low-income countries have questioned the
‘‘transferability’’ of evidence derived from studies conducted
in richer nations [9]. The basis of their concern is their aware-
ness that there can be many differences between patient popu-
lations and in the delivery of health care. Forjuoh et al. have
pointed out that some injury prevention interventions will
have broad transferability, while others will not [10]. They
went on to make suggestions as to which intervention would
be transferable, but they did so on theoretical grounds without
any supporting data.
Features of the typical health care experience of a patient
living in the developing world, as compared with features of
the typical health care experience of a patient in a clinical trial
in a developed country, are shown in Box 1.
There are also important differences in the way inwhich care
is delivered in developing and developed countries. In devel-
oping countries, treatments that would be delivered by doctors
elsewhere are often delivered by medical assistants or clinical
officers. This may or may not have an impact on the effective-
ness of the treatment. Similarly, legislation can be considered a
health care intervention for the prevention of road traffic
injury, but the ‘‘delivery’’ of such legislation (i.e., its enforce-
ment) is often harder to achieve in developing countries for a
multitude of reasons.
As a result of such differences, the most effective treatment
in a randomised controlled trial may not be the most effective
treatment when provided in the developing world. Some treat-
ments will retain muchof their effectiveness ina resource-poor
context; others will not.
One recently updated Cochrane review on the primary repair
of penetrating colon injuries is a case in point [11]. The update
involved the addition of data from one study, which had been
completed since the original version of the review had been
published. This addition introduced a much greater level of
heterogeneity. The likely explanation for this, in the
opinion of the reviewers, was that the new study was the
only one in which the intervention had been applied in a devel-
oping country, which had imposed a number of limitations on
its delivery.
Rather than implying that a review’s conclusions are
globally applicable, perhaps this is one of those circumstances
where it would be more appropriate if reviewers concluded
Box 1. Comparison of the Health Care Experiences of Patients in the
Less Developed and Developed Worlds
Features of the typical health care experience of a patient living in
the less developed world include
  late presentation
  self-medication of ‘‘prescription’’ drugs or traditional treatments
  poor facilities may delay diagnosis
  referral (if needed) not easily arranged
  if a child, may be malnourished
  if a woman, may be anaemic
  will experience problems because of shortages of trained staff
  ...and because of poor infection control
  ...and because of a lack of follow-up care
  patient may be unable (e.g., because of lack of funds) to fully
adhere to treatment.
Features of the typical health care experience of a patient in a clinical
trial in a developed country include
  none of the above
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ness of this intervention in the countries and setting where
the included studies were conducted, and in places that are
similar in terms of the resources available.’’
What Can Be Done?
It is, of course, vital that more research of quality and relev-
ance is conducted in developing countries, but the writers of
systematic reviewers also have much to do. We need to find
ways to make a good product better, and we must do more to
make sure that people in the majority world are able to access
the reviews that are published. In order for progress to be
made, the following questions require more attention than
they have received up to now.
Authors
How can we involve more people from developing countries in
the writing and peer reviewing of systematic reviews? For
example, how can we continue to build on progress made on
international activity within the Cochrane Collaboration [12]
(see Table 1).
Titles
How can we get more reviews written on (a) health problems
that are priorities, and (b) interventions that are affordable
and feasible in the majority world?
Context
Should reviews focus on specific contexts in relation to the
location of the condition and the delivery of the intervention?
Background sections
How can we encourage reviewers to look at conditions/
interventions globally, and not just as they affect the United
States and Western Europe?
Search for studies
How can we make it easier to find and review data from
research done in developing countries?
Analysis
Should reviewers be encouraged to consider whether hetero-
geneity between study results might be due to differences in
underlying resources?
Conclusions
Should conclusions address whether any recommendations
apply everywhere, or just in settings similar to those in which
the included studies were done? Or is this beyond the recom-
mendations of a review?
Dissemination of the Findings of Reviews
Is this best done by circulating the reviews themselves, or are
reviews merely a stage in the production of more accessible
evidence-based health information materials? For example,
the World Health Organization’s Reproductive Health Library,
available on CD-ROM, includes selected Cochrane reviews
but also summaries and commentaries that have been specially
prepared to provide a developing world perspective. The
BMJ’s Clinical Evidence produces other summaries of the
evidence (for example, often integrating the findings of
Cochrane Reviews into answers to clinical questions), and
aims to prepare these in user-friendly formats and languages.
Are more initiatives like these needed?
Research
Research is needed on the impact of systematic reviews on
practice in the developing world. We need to assess: What pro-
portion of reviews are relevant to health care in low-resource
settings? Are evidence-based sources used to set policy in dif-
ferent countries? How widely are the Cochrane Library and/or
Cochrane reviews used by health care workers, and what are
the barriers to use? How widely are these resources used by
other people involved in decisions about health care, including
patients, their carers, and policy makers? Has the use of
Cochrane evidence influenced practice? What do these users
and potential users think would make reviews more useful?
Conclusion
When so-called developing countries first gained freedom
from their colonial oppressors, Ernst Schumacher pointed out
that there was a need, not for the ‘‘best’’ technology, but for
‘‘appropriate’’ technology [13]. When it comes to health care,
practitioners and patients of these countries need and deserve
nothing less than the most ‘‘appropriate evidence’’.
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Table 1. Number of People Actively Involved in Cochrane Collaborative
Review Groups
Year Total number
of people
People in low- and
middle-income countries
2000 5,437 309
2002 7,728 553
2003 9,279 758
2004 11,517 1,078
Data used in this table are from [12].
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